NCT03402152View on ClinicalTrials.gov

NRX101 Glx Biomarker Validation Study

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

January 1, 2021

Study Completion Date

June 1, 2021

Conditions
Bipolar DepressionSuicidal Ideation
Interventions
DRUG

NRX-101

NRX-101, a fixed dose combination of D-cycloserine+lurasidone will be given twice a day by mouth

DRUG

Lurasidone HCl

Lurasidone HCl will be given twice a day by mouth

DRUG

Placebo

Placebo oral capsule

Trial Locations (1)

10032

New York State Psychiatric Institute, New York

Sponsors

Lead Sponsor

NeuroRx, Inc.
All Listed Sponsors
collaborator

Target Health Inc.

INDUSTRY

lead

NeuroRx, Inc.

INDUSTRY

NCT03402152 - NRX101 Glx Biomarker Validation Study | Biotech Hunter | Biotech Hunter